Non-Nucleoside Reverse Transcriptase Inhibitors

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

HIV Integrase Inhibitors

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor

Organic Anion Transporter 1 Inhibitors

Organic Anion Transporter 3 Inhibitors

HIV Infections

<section class="Section" data-sectioncode="34089-3"><a name="ID_527ee747-f4aa-4978-b75a-5671b5381abc"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>CABENUVA contains cabotegravir extended-release injectable suspension, an HIV INSTI, co-packaged with rilpivirine extended-release injectable suspension, an HIV NNRTI.CabotegravirThe chemical name for cabotegravir is (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide. The empirical formula is C19H17F2N3O5 and the molecular weight is 405.35 g/mol. It has the following structural formula:<div class="Figure"><a name="id1294023063"></a><img alt="Cabotegravir chemical structure" src="cabenuva-spl-graphic-01.jpg"/></div>Cabotegravir extended-release injectable suspension is a white to light pink free-flowing suspension for intramuscular injection in a sterile single-dose vial. Each vial contains 2 mL or 3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol (35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL), and Water for Injection.The vial stoppers are not made with natural rubber latex.RilpivirineThe chemical name for rilpivirine is 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile. Its molecular formula is C22H18N6 and its molecular weight is 366.42. Rilpivirine has the following structural formula:<div class="Figure"><a name="id-1903594686"></a><img alt="Rilpivirine chemical structure" src="cabenuva-spl-graphic-02.jpg"/></div>Rilpivirine extended-release injectable suspension is a white to off-white suspension for intramuscular injection. Each sterile single-dose vial contains 2 mL or 3 mL of the following: rilpivirine 300 mg/mL and the following inactive ingredients: citric acid monohydrate (1 mg/mL), poloxamer 338 (50 mg/mL), Water for Injection, glucose monohydrate to ensure isotonicity, sodium dihydrogen phosphate monohydrate, and sodium hydroxide to adjust pH.The vial stoppers are not made with natural rubber latex.</section>

Cabenuva

rilpivirine

cabotegravir

Apretude

3 ML cabotegravir 200 MG/ML Injection

3 ML cabotegravir 200 MG/ML Injection [Apretude]

2 ML cabotegravir 200 MG/ML Injection

3 ML rilpivirine 300 MG/ML Injection

2 ML rilpivirine 300 MG/ML Injection

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Reimbursement Information

Pharmacy List 

How To Order Cabenuva

Billing & Coding Guide 

Reimbursement Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

PA Checklist 

Cabenuva Enrollment Form 

Other HCP Resources: Access

ViiVConnect Online Portal - HCP Office 

Enroll in Patient Savings Program 

Other HCP Resources 

About Cabenuva

Side Effects

Cabenuva Start Guide 

Patient Stories 

Patient Brochure 

Doctor Discussion Guide 

Alternative Site for Administration (ASA) Locator

Instructions For Use: HIV